News From NPR

Many political leaders say the solution for failing school systems is a takeover. But can mayors, governors or other government leaders actually fix broken schools? Guest host Celeste Headlee discusses the expectations and consequences of school takeovers with Emily Richmond of the National Education Writers Association.

Transcript

CELESTE HEADLEE, HOST:

And now we'll turn from New Jersey to Detroit, where tensions are really building around the public school system there. The U.S. Department of Education is looking into whether recent school closures have disproportionately hurt black and Latino students. Also, an emergency financial manager is shaking things up at Detroit Public Schools after getting some new authority from the state.

Here to explain is Jerome Vaughn, news director at member station WDET in Detroit. Welcome back, Jerome.

Transcript

CELESTE HEADLEE, HOST:

This is TELL ME MORE from NPR News. I'm Celeste Headlee. Michel Martin is away. Coming up, we'll talk about school takeovers and whether or not taking a drastic action like that really fixes broken schools. But first we'll bring you up to date on the latest political news. There is a lot going on both here and overseas - the debate over gun control, immigration, and a little saber rattling from North Korea.

Transcript

CELESTE HEADLEE, HOST:

Now it's time for a Wisdom Watch conversation. That's a part of the program where we talk to those who've made a difference with their work. Today we're talking with Clinton Galloway. He's the author of the book "Anatomy of a Hustle: Cable Comes to South Central L.A."

A decision by India's Supreme Court to reject Novartis AG's bid to patent a version of one cancer drug could lead to more exports of cheap medicine from that country to "poor people across the developing world," the BBC writes.

NPR's Julie McCarthy tells our Newscast Desk that the ruling, announced Monday, ends a six-year legal battle that has been closely watched by pharmaceutical firms, humanitarian aid organizations and generic drug manufacturers.

She adds that: